Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Pharma-Skan is a Danish CMO serving large corporations in the pharmaceutical and life sciences industries. With 45 years of consistent performance, the company specializes in the production, filling and packaging of liquid and sterile pharmaceuticals and oral liquids, as well as handling raw materials for both human and veterinary applications.
Skan-Medic, also based in Denmark, manufactures a range of OTC creams, lotions, ointments and other pharmacy-related products, including the patented Marselisborg Cream skin lotion, sold to pharmacies in Denmark.
The product portfolio includes both private label products and recurring contract work for large international pharmaceutical companies, such as the patented potassium chloride oral solution used to treat potassium deficiency, surface disinfectant ethanol for industrial cleaning and boar semen extenders. Operations are carried out in dedicated rooms for each stage of the process — sterile manufacturing, galenic formulation, packaging and quality control — backed by an experienced team with deep industry knowledge.
Brygge Partners is a Danish family office focused on long-term, mid-market acquisitions in the Nordic region, taking a hands-on approach to nurture and develop its portfolio companies.
Oaklins’ team in Denmark acted as the strategic and financial advisor to the owners of Pharma-Skan and Skan-Medic in this transaction.
Susanne Rasmussen
Co-owner, Pharma-Skan & Skan-Medic
Talk to the deal team
Kim Harpøth Jespersen
Oaklins Beierholm
Related deals
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more